3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
76
Carcinoma, Hepatocellular
47
Ovarian Neoplasms
40
Carcinoma, Non-Small-Cell Lung
26
Neoplasms
22
Fallopian Tube Neoplasms
17
Lung Neoplasms
15
Neoplasm Metastasis
13
Breast Neoplasms
13
Glioblastoma
12
Endometrial Neoplasms
12
Brain Neoplasms
12
Colonic Neoplasms
11
Triple Negative Breast Neoplasms
10
Rectal Neoplasms
10
Uterine Cervical Neoplasms
9
Liver Neoplasms
9
Stomach Neoplasms
8
Colorectal Cancer Metastatic
7
Pancreatic Neoplasms
6
Advanced Solid Tumors
6
Recurrence
5
Melanoma
5
Glioma
5
Carcinoma, Renal Cell
5
Carcinoma, Ovarian Epithelial
5
Biliary Tract Neoplasms
5
Solid Tumor
4
Meningeal Carcinomatosis
4
Gastrointestinal Neoplasms
4
Interventions
Liver Transplantation
2
Blood Specimen Collection
2
esmolol
1
atezolizumab
1
apixaban
1
User-Centered Design
1
Tocopherols
1
Standard of Care
1
Sampling Studies
1
Pravastatin
1
Pharmaceutical Preparations
1
Pentoxifylline
1
Neuropsychological Tests
1
Memantine
1
Losartan
1
Ketoprofen
1
Enoxaparin
1
Endoscopy, Digestive System
1
Diagnostic Imaging
1
Bevacizumab
1
2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fibrosis
×
Bevacizumab
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled